- Investment to accelerate growth amid an increasing market demand for Immunohistochemistry instruments and reagents
- Management will leverage GHO’s extensive healthcare expertise to accelerate R&D, product launches and international expansion
- GHO in partnership with existing investor Excellere Partners will continue to support the Biocare Medical team in accelerating strategic growth initiatives
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, announces its investment in Biocare Medical (“Biocare”), a leading developer of world-class immunohistochemistry (“IHC”) and in situ hybridisation (“ISH”) reagents for cancer diagnosis and chromosomal profiling. Existing investor Excellere Partners, a US-based private equity firm shall remain a significant partner in the company alongside GHO.
With increased investment from GHO and Excellere, Biocare will focus on maintaining its outstanding reputation for scientific expertise, quality and innovation, continuing to grow its core reagent focused product and service portfolio to meet increased customer and industry demand. Additionally, Biocare will look to expand the development and penetration of its instrument offering to further deliver a full suite of reagents and hardware to customers across the globe.
Established in 1997 and based in California, USA, Biocare provides a best-in-class portfolio of IHC and molecular reagents, including tissue-conserving simultaneous multiplex solutions and a comprehensive suite of advanced instruments across the clinical, research and biopharma industries. Renowned for its market leading innovation and quality, the business has experienced rapid and consistent growth since inception, operating within an attractive subsector forecast to hit nearly $3.5 billion within the next five years.
With a shift to precision medical treatment increasing the demand for testing and diagnostics, Biocare is set to accelerate its growth as the next generation of bio-marker focused oncology trials aim to tackle a higher prevalence of chronic disease driven by ageing populations.